CWBR vs. BPTS, ARAV, ARDS, REVB, BPTSY, MBIO, VRPX, NBY, AGRX, and SXTP
Should you be buying CohBar stock or one of its competitors? The main competitors of CohBar include Biophytis (BPTS), Aravive (ARAV), Aridis Pharmaceuticals (ARDS), Revelation Biosciences (REVB), Biophytis (BPTSY), Mustang Bio (MBIO), Virpax Pharmaceuticals (VRPX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical preparations" industry.
CohBar (NASDAQ:CWBR) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
2.5% of CohBar shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 6.5% of CohBar shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Biophytis has a consensus price target of $600.00, indicating a potential upside of ∞. Given Biophytis' higher probable upside, analysts clearly believe Biophytis is more favorable than CohBar.
CohBar has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Biophytis has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
In the previous week, CohBar and CohBar both had 1 articles in the media. CohBar's average media sentiment score of 0.34 beat Biophytis' score of 0.00 indicating that CohBar is being referred to more favorably in the media.
CohBar received 12 more outperform votes than Biophytis when rated by MarketBeat users. However, 100.00% of users gave Biophytis an outperform vote while only 72.00% of users gave CohBar an outperform vote.
Summary
CohBar beats Biophytis on 6 of the 9 factors compared between the two stocks.
Get CohBar News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CWBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
